{"entity":{"id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","aka":[],"tldr":"A phase 2 trial of Volrustomig in cervical cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) is a phase 2 interventional study registered as NCT06943833 by AstraZeneca, with 37 participants enrolled, started 2025-03-31 and due to reach its primary completion in 2028-03-13. Interventions recorded: Volrustomig.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06943833","url":"https://clinicaltrials.gov/study/NCT06943833"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06943833","phase":"2","setting":"A Phase II Single-arm Multi-centre Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum Based, Concurrent Chemoradiation Therapy","sponsor":"AstraZeneca","enrolled":37,"outcomes":[]},"route":"/trials/nct06943833/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}